GSK recalls OTC weight-loss drug alli

Share this article:

GSK announced Thursday that it is voluntarily recalling its weight-loss product, alli, from US and Puerto Rico retail locations due to product-tampering concerns.

The drugmaker said in a statement that it is conducting an investigation with the FDA following inquiries from consumers about bottles of alli that contained “tablets and capsules that were not alli.”

“Safety is our first priority and we are asking retailers and pharmacies to remove all alli from their shelves immediately. We have posted a Consumer Alert on our website, www.myalli.com" President of GSK Consumer Healthcare North America Colin Mackenzie said in a statement.

Consumers who purchased the product are advised to call GSK at 800-671-2554 for a representative who will provide further instruction.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.